iRay Group (688301) Fair Value & Analysis
Healthcare · CN · Market cap 33.1B CNY
Fair value as of: Jul 12, 2026
From 16 valuation models · updated 29 days ago
Share price −17.3% over the past month.
A solid business, but screening 61% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥47.16). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥38.54 – ¥145.74 · fair‑value band ¥27.22 – ¥47.16 · the ¥96.39 price screens above the ¥37.19 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
iRay Group (688301) currently trades at ¥96.39, while our model-based Fair Value estimate is ¥37.19, implying the stock looks roughly 61.4% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, iRay Group generated revenue of 2.5B CNY at a net margin of 27.9%. Revenue grew 42.5% year over year. It earns a return on equity of 11.6%. Net debt stands at 796M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥27.22 (bear case) to ¥47.16 (bull case); at ¥96.39, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 63% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -61%, 688301 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (¥73.57) versus Dividend Discount (¥11.71). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
iRay Group, together with its subsidiaries, researches, develops, produces, sells, and services x-ray system components and micro-display backplanes for use in medical, dental, oncology, veterinary, security, and nondestructive testing applications in China and internationally.
Full company description
iRay Group, together with its subsidiaries, researches, develops, produces, sells, and services x-ray system components and micro-display backplanes for use in medical, dental, oncology, veterinary, security, and nondestructive testing applications in China and internationally. The company offers wireless and tethered radiography, mammography, and dynamic/real-time detectors; linear detector arrays; X-ray and micro focus X-ray sources; high voltage generators; radiation detecting materials; software; and other products. It is also involved in the technology and product development; customer service; and investment and management activities. The company exports its products to approximately 80 countries. The company was formerly known as iRay Technology Company Limited and changed its name to iRay Group in February 2025. iRay Group was incorporated in 2011 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
iRay Group reported revenue of ¥2.3B in FY2025 versus ¥1.2B in FY2021, a compound +18.0%/yr. Reported net income was ¥661M in FY2025, compounding +8.1%/yr from FY2021.
688301 screens 61% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare iRay Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is iRay Group (688301) overvalued or undervalued?
What is the fair value of 688301?
What is the quality score of 688301?
What is the revenue of iRay Group (688301)?
What is the net profit margin of 688301?
Does iRay Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track iRay Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.